Inventory

The Company obtains all of its Angiomax bulk drug substance from Lonza Braine, S.A. (Lonza Braine). Under the terms of the Company's agreement with Lonza Braine, the Company provides forecasts of its annual needs for Angiomax bulk substance 18 months in advance. The Company also has a separate agreement with Ben Venue Laboratories, Inc. and Patheon Italia S.p.A for the fill-finish of Angiomax drug product. As of June 30, 2011, the Company had inventory-related purchase commitments totaling $15.3 million during 2011, $30.2 million during 2012 and $15.1 million during 2013 for Angiomax bulk drug substance.

The major classes of inventory were as follows:



Inventory	June 30, 2011		December 31, 2010
	(in thousands)
Raw materials	$	12,860	$	9,801
Work-in-progress	9,572		7,183
Finished goods	6,729		8,359
Total	$	29,161	$	25,343

The Company reviews inventory, including inventory purchase commitments, for slow moving or obsolete amounts based on expected volume. If annual volume is less than expected, the Company may be required to make additional allowances for excess or obsolete inventory in the future.